Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s12276-018-0053-x http://scihub22266oqcxt.onion/10.1038/s12276-018-0053-x C5938017!5938017 !29674631     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29674631 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29674631 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Exp+Mol+Med 2018 ; 50 (4 ): 1-14 Nephropedia Template TP {{tp|p=29674631 |t=2018. Orally active, species-independent novel A(3) adenosine receptor antagonist protects against kidney injury in db/db mice |pdf=|usr=}}{{29674631 }} gab.com Text Orally active, species-independent novel A(3) adenosine receptor antagonist protects against kidney injury in db/db mice JO: Exp Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=29674631 #FOAvip Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease, and the current pharmacological treatment for DKD is limited to renin-angiotensin system (RAS) inhibitors. Adenosine is detectable in the kidney and is significantly elevated in response to cellular damage. While all 4 known subtypes of adenosine receptors, namely, A(1)AR, A(2a)AR, A(2b)AR, and A(3)AR, are expressed in the kidney, our previous study has demonstrated that a novel, orally active, species-independent, and selective A(3)AR antagonist, LJ-1888, ameliorates unilateral ureteral obstruction-induced tubulointerstitial fibrosis. The present study examined the protective effects of LJ-2698, which has higher affinity and selectivity for A(3)AR than LJ-1888, on DKD. In experiment I, dose-dependent effects of LJ-2698 were examined by orally administering 1.5, 5, or 10?mg/kg for 12 weeks to 8-week-old db/db mice. In experiment II, the effects of LJ-2698 (10?mg/kg) were compared to those of losartan (1.5?mg/kg), which is a standard treatment for patients with DKD. LJ-2698 effectively prevented kidney injuries such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, inflammation, and oxidative stress in diabetic mice as much as losartan. In addition, inhibition of lipid accumulation along with increases in PGC1?, a master regulator of mitochondrial biogenesis, were demonstrated in diabetic mice treated with either LJ-2698 or losartan. These results suggest that LJ-2698, a selective A(3)AR antagonist, may become a novel therapeutic agent against DKD. Twit Text FOAVip Orally active, species-independent novel A(3) adenosine receptor antagonist protects against kidney injury in db/db mice ????Exp Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=29674631 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29674631 #FOAvip English Wikipedia <ref>{{Cite pmid|29674631 }}</ref> Orally active, species-independent novel A(3) adenosine receptor antagonist protects against kidney injury in db/db mice #MMPMID29674631 Dorotea D ; Cho A ; Lee G ; Kwon G ; Lee J ; Sahu PK ; Jeong LS ; Cha DR ; Ha H Exp Mol Med 2018[Apr]; 50 (4 ): 1-14 PMID29674631 show ga Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease, and the current pharmacological treatment for DKD is limited to renin-angiotensin system (RAS) inhibitors. Adenosine is detectable in the kidney and is significantly elevated in response to cellular damage. While all 4 known subtypes of adenosine receptors, namely, A(1)AR, A(2a)AR, A(2b)AR, and A(3)AR, are expressed in the kidney, our previous study has demonstrated that a novel, orally active, species-independent, and selective A(3)AR antagonist, LJ-1888, ameliorates unilateral ureteral obstruction-induced tubulointerstitial fibrosis. The present study examined the protective effects of LJ-2698, which has higher affinity and selectivity for A(3)AR than LJ-1888, on DKD. In experiment I, dose-dependent effects of LJ-2698 were examined by orally administering 1.5, 5, or 10?mg/kg for 12 weeks to 8-week-old db/db mice. In experiment II, the effects of LJ-2698 (10?mg/kg) were compared to those of losartan (1.5?mg/kg), which is a standard treatment for patients with DKD. LJ-2698 effectively prevented kidney injuries such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, inflammation, and oxidative stress in diabetic mice as much as losartan. In addition, inhibition of lipid accumulation along with increases in PGC1?, a master regulator of mitochondrial biogenesis, were demonstrated in diabetic mice treated with either LJ-2698 or losartan. These results suggest that LJ-2698, a selective A(3)AR antagonist, may become a novel therapeutic agent against DKD. |*Kidney/injuries/metabolism/pathology [MESH] |*Receptor, Adenosine A3 [MESH] |Adenosine A3 Receptor Agonists/*pharmacology [MESH] |Adenosine/*pharmacology [MESH] |Administration, Oral [MESH] |Animals [MESH] |Diabetic Nephropathies/*drug therapy/metabolism/pathology [MESH] |Dose-Response Relationship, Drug [MESH] |Male [MESH] |Mice [MESH]Orally active, species-independent novel A(3) adenosine receptor antag(epmc).pdf DeepDyve Pubget Overpricing